{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:59:34Z","timestamp":1791399574350,"version":"4.3.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11523-024-01076-7","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T03:40:27Z","timestamp":1718768427000},"page":"711-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4420-0958","authenticated-orcid":false,"given":"Abdulazeez","family":"Salawu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoghan R.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmail","family":"Al-Ezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Genta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Vornicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limore","family":"Arones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey A.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni R.","family":"Abdul Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"issue":"9829","key":"1076_CR1","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(12)60651-5.","journal-title":"Lancet"},{"issue":"10028","key":"1076_CR2","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Schoffski","year":"2016","unstructured":"Schoffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(15)01283-0.","journal-title":"Lancet"},{"issue":"8","key":"1076_CR3","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786\u201393. https:\/\/doi.org\/10.1200\/JCO.2015.62.4734.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1076_CR4","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2020.1707","volume":"323","author":"WD Tap","year":"2020","unstructured":"Tap WD, Wagner AJ, Schoffski P, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE Randomized Clinical Trial. JAMA. 2020;323(13):1266\u201376. https:\/\/doi.org\/10.1001\/jama.2020.1707.","journal-title":"JAMA"},{"issue":"23","key":"1076_CR5","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","volume":"120","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621\u201334. https:\/\/doi.org\/10.1182\/blood-2012-05-429506.","journal-title":"Blood"},{"issue":"2","key":"1076_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1006\/excr.1999.4672","volume":"253","author":"S Lain","year":"1999","unstructured":"Lain S, Xirodimas D, Lane DP. Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. Exp Cell Res. 1999;253(2):315\u201324. https:\/\/doi.org\/10.1006\/excr.1999.4672.","journal-title":"Exp Cell Res"},{"issue":"2","key":"1076_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/s1359-6446(02)02562-x","volume":"8","author":"TR Kau","year":"2003","unstructured":"Kau TR, Silver PA. Nuclear transport as a target for cell growth. Drug Discov Today. 2003;8(2):78\u201385. https:\/\/doi.org\/10.1016\/s1359-6446(02)02562-x.","journal-title":"Drug Discov Today"},{"issue":"34","key":"1076_CR8","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","volume":"34","author":"AR Abdul Razak","year":"2016","unstructured":"Abdul Razak AR, Mau-Soerensen M, Gabrail NY, et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34(34):4142\u201350. https:\/\/doi.org\/10.1200\/JCO.2015.65.3949.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1076_CR9","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1200\/JCO.21.01829","volume":"40","author":"MM Gounder","year":"2022","unstructured":"Gounder MM, Razak AA, Somaiah N, et al. Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2022;40(22):2479\u201390. https:\/\/doi.org\/10.1200\/JCO.21.01829.","journal-title":"J Clin Oncol"},{"issue":"35","key":"1076_CR10","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1200\/JCO.22.02906","volume":"41","author":"I Vergote","year":"2023","unstructured":"Vergote I, Perez-Fidalgo JA, Hamilton EP, et al. Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. J Clin Oncol. 2023;41(35):5400\u201310. https:\/\/doi.org\/10.1200\/JCO.22.02906.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1076_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/CCO.0000000000000866","volume":"34","author":"SR Goldsmith","year":"2022","unstructured":"Goldsmith SR, Liu L, Shiah K. Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas. Curr Opin Oncol. 2022;34(5):524\u201330. https:\/\/doi.org\/10.1097\/CCO.0000000000000866.","journal-title":"Curr Opin Oncol"},{"issue":"26","key":"1076_CR12","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","volume":"34","author":"MM Gounder","year":"2016","unstructured":"Gounder MM, Zer A, Tap WD, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016;34(26):3166\u201374. https:\/\/doi.org\/10.1200\/JCO.2016.67.6346.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1076_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10637-021-01184-5","volume":"40","author":"R Dev","year":"2022","unstructured":"Dev R, Zhong LL, Zarifa A, et al. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs. 2022;40(1):124\u201333. https:\/\/doi.org\/10.1007\/s10637-021-01184-5.","journal-title":"Invest New Drugs"},{"issue":"20","key":"1076_CR14","doi-asserted-by":"publisher","first-page":"20299","DOI":"10.1002\/cam4.6589","volume":"12","author":"A Hernando-Calvo","year":"2023","unstructured":"Hernando-Calvo A, Malone E, Day D, et al. Selinexor for the treatment of recurrent or metastatic salivary gland tumors: results from the GEMS-001 clinical trial. Cancer Med. 2023;12(20):20299\u2013310. https:\/\/doi.org\/10.1002\/cam4.6589.","journal-title":"Cancer Med"},{"issue":"7","key":"1076_CR15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1634\/theoncologist.2019-0231","volume":"24","author":"M Shafique","year":"2019","unstructured":"Shafique M, Ismail-Khan R, Extermann M, et al. A Phase II trial of selinexor (KPT-330) for metastatic triple-negative breast cancer. Oncologist. 2019;24(7):887-e416. https:\/\/doi.org\/10.1634\/theoncologist.2019-0231.","journal-title":"Oncologist"},{"key":"1076_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ejca.2020.10.032","volume":"144","author":"J Lewin","year":"2021","unstructured":"Lewin J, Malone E, Al-Ezzi E, et al. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS). Eur J Cancer. 2021;144:360\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2020.10.032.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1076_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1076_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"1076_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40271-022-00584-w","volume":"15","author":"CD Coon","year":"2022","unstructured":"Coon CD, Schlichting M, Zhang X. Interpreting within-patient changes on the EORTC QLQ-C30 and EORTC QLQ-LC13. The patient. 2022;15(6):691\u2013702. https:\/\/doi.org\/10.1007\/s40271-022-00584-w.","journal-title":"The patient."},{"issue":"6","key":"1076_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2023.100963","volume":"47","author":"G Bogani","year":"2023","unstructured":"Bogani G, Monk BJ, Coleman RL, et al. Selinexor in patients with advanced and recurrent endometrial cancer. Curr Probl Cancer. 2023;47(6): 100963. https:\/\/doi.org\/10.1016\/j.currproblcancer.2023.100963.","journal-title":"Curr Probl Cancer"},{"issue":"5","key":"1076_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100258","volume":"6","author":"E Younger","year":"2021","unstructured":"Younger E, Jones RL, den Hollander D, et al. Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study. ESMO Open. 2021;6(5): 100258. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100258.","journal-title":"ESMO Open."},{"issue":"17","key":"1076_CR22","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1002\/cncr.29426","volume":"121","author":"C Coens","year":"2015","unstructured":"Coens C, van der Graaf WT, Blay JY, et al. Health-related quality-of-life results from PALETTE: a randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Cancer. 2015;121(17):2933\u201341. https:\/\/doi.org\/10.1002\/cncr.29426.","journal-title":"Cancer"},{"issue":"22","key":"1076_CR23","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.2217\/fon-2021-0284","volume":"17","author":"M Gounder","year":"2021","unstructured":"Gounder M, Abdul Razak AR, Gilligan AM, et al. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncol. 2021;17(22):2923\u201339. https:\/\/doi.org\/10.2217\/fon-2021-0284.","journal-title":"Future Oncol"},{"issue":"5","key":"1076_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/sj.bjc.6602112","volume":"91","author":"SA Hussain","year":"2004","unstructured":"Hussain SA, Stocken DD, Riley P, et al. A phase I\/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004;91(5):844\u20139. https:\/\/doi.org\/10.1038\/sj.bjc.6602112.","journal-title":"Br J Cancer"},{"key":"1076_CR25","doi-asserted-by":"publisher","first-page":"vi487","DOI":"10.1093\/annonc\/mdw388.15","volume":"27","author":"RGMVD Azevedo","year":"2016","unstructured":"Azevedo RGMVD, Fraile N, Neto ES, et al. Tolerability of modified gemcitabine\/docetaxel (split-dose) in patients with advanced soft tissue sarcomas. Ann Oncol. 2016;27:vi487. https:\/\/doi.org\/10.1093\/annonc\/mdw388.15.","journal-title":"Ann Oncol"},{"key":"1076_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/532478","volume":"2015","author":"MA Dickson","year":"2015","unstructured":"Dickson MA, D\u2019Adamo DR, Keohan ML, et al. Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma. 2015;2015: 532478. https:\/\/doi.org\/10.1155\/2015\/532478.","journal-title":"Sarcoma"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01076-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01076-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01076-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T14:13:04Z","timestamp":1726150384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01076-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1076"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01076-7","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"21 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"METSSAR was an investigator-initiated trial at Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Partial funding as well as investigational product support was provided by Karyopharm Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A. Salawu has received research funding from PTC Therapeutics; speaker fees from Medison pharma; and advisory board\/consulting fees from Boehringer Ingelheim, Amgen, Bayer, Astellas, Taiho, and Knight Therapeutics. G. Watson has received travel grants from Bristol Meyer Squibb, Abbvie; Honoraria from Pfizer, Astra Zeneca, Knight Therapeutics, Novartis, Boehringer Ingelheim, Gilead and advisory board\/consulting fees from Novartis and Boehringer Ingelheim. A.R. Abdul Razak has received research funding from Boehringer Ingelheim, Deciphera, Karyopharm Therapeutics, Pfizer, Roche\/Genentech, Bristol-Myers Squibb, MedImmune, Amgen, GlaxoSmithKline, Blueprint Medicines, Merck, Abbvie, Adaptimmune, Iterion Therapeutics, 23&Me, Rain Therapeutics, Neoleukin Therapeutics, Daiichi Sankyo, Symphogen, Frontier Therapeutics; and advisory board\/consulting fees from Adaptimmune, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Medison, Inhibrx; and payment for expert testimony from Medison. E.R. Malone, E. Al-Ezzi, S. Genta, O. Vornicova, L. Wang, L. Arones, M. Phillips, J. Lee, and A.A. Gupta declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study protocol was approved by the Research Ethics Board (REB) at the Princess Margaret Cancer Centre, Toronto. All participants gave written informed consent, and the trial was performed in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Informed Consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conception and design of study: A.R. Abdul Razak, E.R. Malone. Acquisition of data: A. Salawu, E. Al-Ezzi, S. Genta, O. Vornicova, L. Wang, L. Arones, M. Phillips, J. Lee, G. Watson, A.A. Gupta, A.R. Abdul Razak. Analysis and\/or interpretation of data: A. Salawu, E.R. Malone, E. Al-Ezzi, S. Genta, O. Vornicova, L. Wang, L. Arones, M. Phillips, J. Lee, G. Watson, A.A. Gupta, A.R. Abdul Razak. Approval of the version of the manuscript to be published: A. Salawu, E.R. Malone, E. Al-Ezzi, S. Genta, O. Vornicova, L. Wang, L. Arones, M. Phillips, J. Lee, G. Watson, A.A. Gupta, A.R. Abdul Razak.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}